

19<sup>th</sup> Annual  
**McMaster Hematology & Thromboembolism Update**



HEALTH SCIENCES  
 Continuing Professional Development



At the end of this learning activity the learners will be able to:

- Identify and discuss current trends in hematology and thromboembolism.
- Recognize which hematologic/thrombotic issues can be managed in primary care and which should be referred to a specialist.
- Provide practical guidance on the diagnosis and management of common hematological conditions, with a focus on recent innovations.

TOPIC	SESSION-SPECIFIC LEARNING OBJECTIVES	CanMEDS Competency	SPEAKER(S)/ FACULTY
What's new in Thrombosis in 2023	1. Recognize new advances in diagnosis/management of venous thromboembolism over the last year	Medical Expert	Siraj Mithoowani
What's new in benign hematology in 2023	1. Recognize new advances in diagnosis/management of benign hematological disorders over the last year	Medical Expert	Eric Tseng
Hematology and Thrombosis considerations in pregnancy	1. Identify hematology/thrombosis emergencies during pregnancy 2. Initiate appropriate preventive treatment for women at high risk of hematologic or thrombotic complications during pregnancy	Medical Expert, Health Advocate	Kristine Matusiak

19<sup>th</sup> Annual  
**McMaster Hematology &  
 Thromboembolism Update**



HEALTH SCIENCES  
 Continuing Professional  
 Development



Peri-operative hematology and thrombosis considerations	<ol style="list-style-type: none"> <li>1. Prepare an evidence-based peri-operative anticoagulant management plan for patients on warfarin or direct oral anticoagulants</li> <li>2. Assess and select appropriate blood products to support hemostasis during surgery (e.g. plasma, platelets)</li> </ol>	Medical Expert, Scholar	Michelle Zeller and Zachary Liederman
Panel: Complex clinical cases	<ol style="list-style-type: none"> <li>1. Develop an approach to managing challenging cases that expertise from a multidisciplinary team</li> <li>2. Develop strategies to reason through complex clinical cases and balance competing risks of therapy (e.g. bleeding, clotting)</li> </ol>	Medical Expert, Collaborator	Chair: Mark Crowther Vera Dounaevskaia Eric Tseng Deb Siegal
1A Serum Protein Electrophoresis – a practical guide	<ol style="list-style-type: none"> <li>1. Describe the laboratory workup of MGUS including principles of laboratory tests</li> <li>2. Identify patients with MGUS who should be referred to a hematologist</li> <li>3. Describe how to monitor patients with MGUS</li> </ol>	Medical Expert	Shreyash Dalmia
2A Errors in prescribing anticoagulants	<ol style="list-style-type: none"> <li>1. Review indications and dosing of frequently prescribed anticoagulants (DOACs, heparins)</li> <li>2. Discuss common anticoagulant prescribing errors and how to prevent them</li> </ol>	Medical Expert, Health Advocate	Stephanie Carlin
3A Pathogen reduced blood components	<ol style="list-style-type: none"> <li>1. Describe the process of blood product pathogen inactivation at Canadian Blood Services</li> <li>2. Describe the potential benefits of pathogen inactivation and its potential impact on the blood supply and clinical practice</li> </ol>	Medical Expert	Kathryn Webert

19<sup>th</sup> Annual  
**McMaster Hematology & Thromboembolism Update**



HEALTH SCIENCES  
 Continuing Professional Development



4A Heavy Menstrual bleeding – hematology and thrombosis implications	<ol style="list-style-type: none"> <li>1. Select appropriate treatments for iron deficiency secondary to heavy menstrual bleeding</li> <li>2. Recognize when patients require referral to Obstetrics/Gynecology for heavy menstrual bleeding</li> </ol>	Medical Expert, Health Advocate	Menaka Pai
1B Thrombophilia testing in 2023	<ol style="list-style-type: none"> <li>1. Review indications to test for acquired/inherited thrombophilia</li> <li>2. Describe challenges with interpreting thrombophilia testing</li> <li>3. Communicate results of thrombophilia testing in patient-friendly language</li> </ol>	Medical Expert, Communicator	Wendy Lim
2B Restarting anticoagulants after bleeding	<ol style="list-style-type: none"> <li>1. Identify which patients should be restarted on anticoagulant therapy after a major bleeding event</li> <li>2. Develop an approach to restarting anticoagulants after bleeding (i.e. optimal drug, dose, timing)</li> </ol>	Medical Expert	Deborah Siegal
3B Rare blood products	<ol style="list-style-type: none"> <li>1. Describe indications, and potential benefits/harms of transfusing rare blood products (e.g. recombinant Factor VIIa, factor concentrates)</li> </ol>	Medical Expert	Marissa Laureano
4B Upper limb and superficial thrombosis	<ol style="list-style-type: none"> <li>1. Identify patients with superficial thrombosis that should be treated with anticoagulant therapy</li> <li>2. Describe evidence-based management (drug, dose, length of therapy) for superficial venous thrombosis and upper limb DVT</li> </ol>	Medical Expert, Scholar	Rick Ikesaka

19<sup>th</sup> Annual  
**McMaster Hematology & Thromboembolism Update**



HEALTH SCIENCES  
 Continuing Professional  
 Development



<p>A practical approach to the hemoglobin electrophoresis for the non-hematologist</p>	<ol style="list-style-type: none"> <li>1. Develop an approach to interpreting hemoglobin electrophoresis results for sickle cell disease and thalassemia</li> </ol>	<p>Medical Expert</p>	<p>Sarah Patterson</p>
<p>Community management of low-grade hematologic malignancies and quasi-malignancies</p>	<ol style="list-style-type: none"> <li>1. Describe the natural history of indolent hematologic malignancies (e.g. chronic lymphocytic leukemia, myeloproliferative disease) and how to monitor these patients</li> <li>2. Recognize complications of indolent hematologic disease and when to refer to a hematologist</li> </ol>	<p>Medical Expert, Collaborator</p>	<p>Approach to low-grade lymphoid disorders</p>
<p>Liver disease – hematology and thrombosis considerations</p>	<ol style="list-style-type: none"> <li>1. Describe the hematologic and thrombosis complications of cirrhosis</li> <li>2. Develop an approach to managing splanchnic vein thrombosis in patients with liver cirrhosis</li> </ol>	<p>Medical Expert</p>	<p>Vinai Bhagirath</p>